ÂÜÀòÂÒÂ×

Dr. McKew has 27 years of experience developing novel therapeutics where he successfully advanced therapies through preclinical and into clinical development. He is currently Chief Operating Officer of Lumos Pharma. Prior to Lumos Pharma, Dr. McKew was Vice President of Research at aTyr Pharma where he led a research team discovering and advancing protein-based therapeutics for rare diseases. He has also served as Acting Scientific Director for the National Center for Advancing Translational Science (NCATS) intramural group, a part of the National Institute of Health (NIH). At NCATS, his lab¡¯s work on rare diseases and public/private partnerships led to the collaborative advancement of several therapeutic candidates currently being commercialized by pharmaceutical companies. Dr. McKew is also an Adjunct Professor at the Boston University School of Medicine and has previously served as the Chair Elect, Chair and Immediate Past Chair of the American Chemical Society¡¯s Northeastern section. He has over 70 peer-reviewed publications and granted patents. Dr. McKew graduated from State University of New York at Stony Brook with B.S. degrees in Chemistry and Biochemistry, completed his Ph.D. in Organic Chemistry at University of California, Davis and held post-doctoral research positions at the University of Geneva and Firmenich, SA.